





Clontech TaKaRa cellartis



肝脏细胞模型专题（二） Takara 人iPS细胞来源肝脏细胞

宝日医生物技术（北京）有限公司


目录



Takara 人iPS细胞来源肝脏细胞
应用于代谢疾病模型研究

Takara 人iPS细胞来源肝脏细胞
应用于药物代谢研究

Takara :即用的人iPS细胞来源肝脏细胞



- 高度同质化，批次间差异小，拥有14天的实验窗口
- 肝脏细胞(1.2×10^7 cells/管)+包被剂+解冻铺板液+培养液
- 具备成体肝脏细胞功能特征，应用于肝脏代谢疾病模型和ADME-Tox研究

表达标志蛋白质，分泌Alb，具备CYP活性，调控胰岛素和葡萄糖，调控脂质代谢
表达药物代谢机制相关的I相酶、II相酶、转运蛋白等，对毒性药物呈现预期反应

产品货号	产品名称	规格
Y10133	Cellartis® Enhanced hiPS-HEP (from ChiPSC12) v2 Kit	1 Kit
Y10134	Cellartis® Enhanced hiPS-HEP (from ChiPSC18) v2 Kit	1 Kit
Y10135	Cellartis® Enhanced hiPS-HEP (from ChiPSC22) v2 Kit	1 Kit

人iPS细胞来源肝脏细胞


All-in-one型




解冻细胞

应用于慢性-毒性实验和病毒感染实验研究

> 14天的实验窗口



应用一：肝脏代谢疾病研究



肝脏：

- ① 通过储存或释放糖原，对血糖变化作出反应。
- ② 与胰腺相似，肝脏也对胰岛素有所反应。
- ③ 脂肪酸、胆固醇和脂蛋白输送至肝脏并输出。

(当肝脏开始积累这些脂类物质，会导致NAFLD，最终会导致脂肪变性-肝炎-肝硬化)

技术数据：应用于代谢疾病模型

TECH NOTE

Next-generation human iPS cell-derived hepatocytes for metabolic disease modeling



Improved hepatocytes for modeling metabolic disorders

Cells express expected markers and display functional characteristics of mature hepatocytes >>

Functional glucose regulation

Cells demonstrate normal insulin response and functional glucose regulation >>

Functional lipid metabolism

Cells demonstrate important features of lipid metabolism >>

An appropriate model for progressing NAFLD

Upon induction of steatosis, cells show elevated triglycerides and TNF α >>

全文链接：

<https://www.takarabio.com/learning-centers/stem-cell-research/stem-cell-technical-notes/hepatocytes-for-disease-modeling>

人iPS细胞来源肝脏细胞：新型的代谢疾病模型

Enhanced hiPS-HEP:

表达预期的标志物和呈现成熟肝脏细胞的功能特征>>

显示功能性的葡萄糖调节>>

显示功能性的脂质代谢>>

作为NAFLD模型>>

人iPS细胞来源肝脏细胞：代谢疾病模型


成熟肝脏细胞特征

Enhanced hiPS-HEP表达多种肝脏细胞特异性标志物 (HNF4 α ; ASGPR1; Alb; α 1AT)

hphep

HNF4 α


DAPI



C18

HNF4 α


DAPI



hphep

ASGPR1


DAPI



C18

ASGPR1


DAPI



hphep

Albumin


DAPI



Enhanced hiPS-HEP
cells (from C18)

Albumin


DAPI



hphep

α 1AT


DAPI



Enhanced hiPS-HEP
cells (from C18)

α 1AT

DAPI



(hphep d1; C18 d12)


hphep: human primary hepatocytes (BioreclamationIVT)

C12/C18/C22: Enhanced hiPS-HEP cells from C12, C18, C22(Takara)

人iPS细胞来源肝脏细胞：代谢疾病模型

功能性葡萄糖调节



Enhanced hiPS-HEP可以储存糖原，表达涉及糖原代谢、糖异生、胰岛素信号的基因，通过磷酸化Akt对胰岛素反应



人iPS细胞来源肝脏细胞：代谢疾病模型

功能性的脂质代谢



Enhanced hiPS-HEP可以摄取LDL，表达胆固醇、脂肪酸代谢调节相关的基因



人iPS细胞来源肝脏细胞：代谢疾病模型

NAFLD模型

Enhanced hiPS-HEP在高油酸处理后，类似如NAFLD，积累了甘油三酯；
在MCD培养基处理后，如预期显示炎症因子TNF α 的表达升高，模拟NAFLD中脂肪变性的进程




WME: Williams medium E

MCD: Methionine-&choline-deficient WME

蛋氨酸胆碱缺乏培养基，可诱导TNF α 表达，类似脂肪变性进程

(Sahai et al. 2006)

应用二：药物ADME-Tox研究



药物在肝脏内的代谢阶段：

Phase I:

氧化、还原、水解等反应直接改变物质的基团或使之分解，激发活性或毒性

Phase I Enzyme:

CYP450 enzymes(细胞色素P450酶)

Phase II:

药物进一步与内源性结合剂的结合反应，使药物毒性或活性降低和极性增加，进而经由尿液或胆汁排出体外

Phase II Enzyme:

SULT (碘基转移酶)

UGT (尿苷二磷酸葡萄糖醛酸转移酶)

技术数据：应用于药物代谢研究

TECH NOTE

Next-generation human iPS cell-derived hepatocytes for long-term drug metabolism studies



Long-term expression of drug-metabolizing machinery

Cellartis enhanced hiPS-HEP cells express hepatic uptake and efflux transporters, phase II enzymes, and cytochrome P450 (CYP) enzymes until Day 20 post-thawing.

High batch-to-batch consistency

Cellartis enhanced hiPS-HEP cells display consistent CYP activity levels and high homogeneity between batches.

Interindividual variation in CYP activities due to availability of three donor lines

Cellartis enhanced hiPS-HEP cells derived from different hiPSC lines display different CYP activity profiles, as expected.

全文链接：

<https://www.takarabio.com/learning-centers/stem-cell-research/stem-cell-technical-notes/hepatocytes-for-drug-metabolism-studies>

人iPS细胞来源肝脏细胞：长时间的药物代谢研究


Enhanced hiPS-HEP:

长时间表达药物代谢机制（CYP酶、II相酶、转运蛋白等）>>
不同批次间差异小，CYP活性水平一致>>
三种供体来源细胞如预期显示不同的CYP活性谱>>

人iPS细胞来源肝脏细胞：药物代谢模型

CYP酶


Enhanced hiPS-HEP长时间具备CYP酶活性，同一供体批次间差异小，CYP酶活性稳定
三种供体来源Enhanced hiPS-HEP具备不同的CYP活性谱，反映了个体之间的CYP差异



人iPS细胞来源肝脏细胞：药物代谢模型

II相酶

Enhanced hiPS-HEP
长时间维持II相酶活性





转运蛋白

Enhanced hiPS-HEP长时间
表达摄取转运蛋白（上）、
外排转运蛋白（下）

人iPS细胞来源肝脏细胞：药物代谢模型

慢性毒性研究

Enhanced hiPS-HEP对已知的肝毒性药物呈现正确反应，即延长重复给药时间后，灵敏度增加




Hphep (BioreclamationIVT), 3D spheroids
HepaRG (Thermo Fisher Scientific), 2D conditions
Cellartis Enhanced hiPS HEP, 2D conditions

人iPS细胞来源肝脏细胞：毒性评价模型


对已知的肝脏毒性药物呈现高特异性和高敏感性

可区分有毒和无毒的结构类似物



获得的体外毒性检测数据与临床反应相关

对引起临床肝脏受损的化合物呈现预期反应



文献：人iPS细胞来源肝脏细胞

1. Asplund, A. *et al.* One Standardized Differentiation Procedure Robustly Generates Homogenous Hepatocyte Cultures Displaying Metabolic Diversity from a Large Panel of Human Pluripotent Stem Cells. *Stem Cell Rev. Reports* **12**, 90 - 104 (2016).
2. Starokozhko, V., Hemmingsen, M., Larsen, L., Mohanty, S., Merema, M., Pimentel, R. C& Dufva, M.. Differentiation of human - induced pluripotent stem cell under flow conditions to mature hepatocytes for liver tissue engineering. *Journal of tissue engineering and regenerative medicine*, **12**(5), 1273–1284 (2018).
3. Ghosheh, N. *et al.* Highly Synchronized Expression of Lineage-Specific Genes during *In Vitro* Hepatic Differentiation of Human Pluripotent Stem Cell Lines. *Stem Cells Int.* **2016**, 1 - 22 (2016).
4. Ghosheh, Nidal, *et al.* Comparative transcriptomics of hepatic differentiation of human pluripotent stem cells and adult human liver tissue. *Physiological genomics*, **49**(8), 430–446(2017).
5. Ulvestad, M. *et al.* Drug metabolizing enzyme and transporter protein profiles of hepatocytes derived from human embryonic and induced pluripotent stem cells. *Biochem. Pharmacol.* **86**, 691 - 702 (2013).
6. Yildirimman, Reha, *et al.*. Human embryonic stem cell derived hepatocyte-like cells as a tool for *in vitro* hazard assessment of chemical carcinogenicity. *Toxicological Sciences*, **124**(2), 278–290(2011).
7. Holmgren, G. *et al.* Long-term chronic toxicity testing using human pluripotent stem cell-derived hepatocytes. *Drug. Metab. Dispos.* **42**, 1401 - 1406 (2014).

更多文献信息:

<https://www.takarabio.com/learning-centers/stem-cell-research/stem-cell-citations/cellartis-enhanced-ipscs-hepatocytes>



that's
GOOD
science!®

Clontech **Takara** cellartis